<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123968</url>
  </required_header>
  <id_info>
    <org_study_id>RV 172</org_study_id>
    <secondary_id>10381</secondary_id>
    <nct_id>NCT00123968</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults</brief_title>
  <official_title>A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Boosted by a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Adult Volunteers in East Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety of and immune response to an&#xD;
      investigational HIV vaccine, VRC-HIVDNA016-00-VP, and a vaccine booster, VRC-HIVADV014-00-VP,&#xD;
      in HIV uninfected adults from Kenya, Tanzania, and Uganda.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The worldwide HIV/AIDS epidemic may only be controlled through development of a safe and&#xD;
      effective vaccine that will prevent HIV infection. This study will evaluate the safety and&#xD;
      immunogenicity of an experimental adenovirus-vectored multiclade HIV vaccine,&#xD;
      VRC-HIVADV014-00-VP, followed with or without a similarly structured DNA plasmid HIV vaccine,&#xD;
      VRC-HIVDNA016-00-VP. The DNA in both vaccines codes for proteins from HIV subtypes A, B, and&#xD;
      C, which together represent 90% of new HIV infections in the world. HIV uninfected volunteers&#xD;
      will be recruited in the East African nations of Kenya, Tanzania, and Uganda.&#xD;
&#xD;
      This study will comprise two parts, 1 and 2. Part 1 will enroll 144 participants who will be&#xD;
      randomly assigned to one of four different groups:&#xD;
&#xD;
        -  Group 1A participants will receive a low dose of the adenovirus-vectored HIV vaccine or&#xD;
           placebo at study entry.&#xD;
&#xD;
        -  Group 1B participants will receive a higher dose of the adenovirus-vectored HIV vaccine&#xD;
           or placebo at study entry.&#xD;
&#xD;
        -  Group 1C will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and&#xD;
           56. They will also receive either a low dose of the adenovirus-vectored HIV vaccine or&#xD;
           placebo at Day 168.&#xD;
&#xD;
        -  Group 1D will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and&#xD;
           56. They will also receive either a higher dose of the adenovirus-vectored HIV vaccine&#xD;
           or placebo at Day 168.&#xD;
&#xD;
      Enrollment into Part 2 (Groups 2A and 2B) will begin after the completion of the safety data&#xD;
      evaluation of Groups 3 and 4 and after Part A has been fully enrolled. Group 2A participants&#xD;
      will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will&#xD;
      also receive either a low dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.&#xD;
&#xD;
      There will be 11 study visits over 14 to 16 months for Parts 1 and 2. All study visits will&#xD;
      include a physical exam, medical and medication history, vital signs measurement, lymph node&#xD;
      assessment, HIV and pregnancy counseling, and blood and urine collection. A home visit will&#xD;
      also occur at study entry. A 3-day diary card to report side effects will be completed by&#xD;
      participants at study entry and on Days 28, 56, 168, and 210.&#xD;
&#xD;
      There will be 14 study visits for Groups 3, 4, and 5; these visits will include the same&#xD;
      tests and assessments as for Groups 1 and 2.&#xD;
&#xD;
      As per an amendment (dated December 19, 2005), follow-up for this study will be extended. The&#xD;
      purpose for this extension is to examine in greater depth the efficacy of the vaccine.&#xD;
      Specifically, investigators will be exploring whether there is a persistent immune response&#xD;
      in participants who received the vaccine as well as if new or boosted responses to the&#xD;
      adenovirus vaccine are persistent. The extended follow-up will last for 2 years with clinic&#xD;
      visits every 4 months. During visits blood will be drawn for laboratory tests, including HIV&#xD;
      testing. Participants will also be informed of ways to reduce their risk of contracting HIV.&#xD;
      Two weeks after each visit, participants will be asked to come to the study site for a short&#xD;
      post HIV test counseling visit. There will be a total of 6 visits per year, 3 follow-up&#xD;
      visits, and 3 post HIV test counseling visits. There will be no more vaccinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local reactogenicity signs and symptoms</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic reactogenicity signs and symptoms</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measures of safety</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse and serious adverse experiences</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfractionated IFN-gamma ELISPOT responses to HIV-1</measure>
    <time_frame>At Day 196</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ and CD8+ T cell responses to HIV-1, as measured by flow cytometry-based intracellular cytokine staining (ICS) assay</measure>
    <time_frame>At Day 196</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a higher dose of the adenovirus-vectored HIV vaccine or placebo at study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a low dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a higher dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA plasmid vaccine at study entry and Days 28 and 56. They will also receive a low dose of the adenovirus-vectored HIV vaccine at Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the DNA plasmid vaccine placebo at study entry and Days 28 and 56. They will also receive a the adenovirus-vectored HIV vaccine placebo at Day 168.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVDNA016-00-VP</intervention_name>
    <description>1x10^11 per unit vaccine administered intramuscularly via Bioinjector</description>
    <arm_group_label>1A</arm_group_label>
    <arm_group_label>1B</arm_group_label>
    <arm_group_label>1C</arm_group_label>
    <arm_group_label>1D</arm_group_label>
    <arm_group_label>2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVADV014-00-VP</intervention_name>
    <description>4 mg administered intramuscularly via injection</description>
    <arm_group_label>1C</arm_group_label>
    <arm_group_label>1D</arm_group_label>
    <arm_group_label>2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-DILUENT013-DIL-VP</intervention_name>
    <description>Administered intramuscularly via Bioinjector</description>
    <arm_group_label>1A</arm_group_label>
    <arm_group_label>1B</arm_group_label>
    <arm_group_label>1C</arm_group_label>
    <arm_group_label>1D</arm_group_label>
    <arm_group_label>2A</arm_group_label>
    <arm_group_label>2B</arm_group_label>
    <other_name>VRC-HIVDNA016-00-VP placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVADV014-00-VP placebo</intervention_name>
    <description>4 mg administered intramuscularly via injection</description>
    <arm_group_label>1C</arm_group_label>
    <arm_group_label>1D</arm_group_label>
    <arm_group_label>2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Willing to follow all the requirements of the study and available for follow-up for&#xD;
             the duration of the study (14 to 16 months)&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Willing to undergo HIV testing and counseling and willing to receive HIV test results&#xD;
&#xD;
          -  Willing to not engage in high-risk behavior for HIV infection during the study&#xD;
&#xD;
          -  Willing to provide location and be visited at home&#xD;
&#xD;
          -  Willing to be identified with picture identification for study purposes&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception&#xD;
&#xD;
          -  Pregnant women and those with conditions which render phlebotomy volumes hazardous&#xD;
             will be allowed to participate using a minimized phlebotomy schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV or HBV infection&#xD;
&#xD;
          -  HIV vaccines in prior HIV vaccine trial&#xD;
&#xD;
          -  Immunosuppressive or cytotoxic medications within the 6 months prior to study entry.&#xD;
             Participants who have used corticosteroid nasal spray for allergic rhinitis or topical&#xD;
             corticosteroids for acute uncomplicated dermatitis are not excluded.&#xD;
&#xD;
          -  Blood products within 120 days prior to study entry&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to study entry&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to first study vaccine administration&#xD;
&#xD;
          -  Medically indicated subunit or killed vaccines or allergy treatment with antigen&#xD;
             injections within 14 days prior to first study vaccine administration&#xD;
&#xD;
          -  Investigational research agents within 30 days prior to first study vaccine&#xD;
             administration&#xD;
&#xD;
          -  Current tuberculosis prophylaxis or therapy&#xD;
&#xD;
          -  Participated in high-risk behavior for HIV infection within 6 months prior to study&#xD;
             entry. More information on this criterion can be found in the protocol.&#xD;
&#xD;
          -  Serious adverse reactions to vaccines, such as anaphylaxis, hives, respiratory&#xD;
             difficulty, angioedema, or abdominal pain&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Unstable asthma or asthma requiring emergent or urgent care, hospitalization,&#xD;
             intubation, or oral or intravenous corticosteroids during the 2 years prior to study&#xD;
             entry&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2. Patients with gestational diabetes are not excluded.&#xD;
&#xD;
          -  Thyroid disease, including removal of thyroid or disease requiring medication within 3&#xD;
             years prior to study entry&#xD;
&#xD;
          -  Serious angioedema within 3 years prior to study entry or disease requiring medication&#xD;
             within 2 years prior to study entry&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Active syphilis&#xD;
&#xD;
          -  Active cancer OR treated cancer that may recur during the duration of the study&#xD;
&#xD;
          -  Seizure disorder. Participants who have had fever-related seizures prior to age 2 are&#xD;
             not excluded.&#xD;
&#xD;
          -  Absence of spleen OR partial or complete lack of splenic function&#xD;
&#xD;
          -  Psychiatric condition that may interfere with the study, including past or present&#xD;
             psychoses, bipolar disorder, or suicidal attempts&#xD;
&#xD;
          -  Any medical, psychiatric, or social condition that, in the opinion of the&#xD;
             investigator, may interfere with the study&#xD;
&#xD;
          -  Any occupational or other responsibility that, in the opinion of the investigator, may&#xD;
             interfere with the study&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or plan to become pregnant&#xD;
&#xD;
          -  Any occupational or other responsibility that, in the opinion of the investigator, may&#xD;
             interfere with the study&#xD;
&#xD;
          -  Incapacitating illness precluding clinic visits&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Prisoners will not be enrolled while incarcerated and if enrolled prior to&#xD;
             incarceration, will not be followed while in confinement. Re-consent will not be&#xD;
             required upon release from prison.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merlin Robb, MD</last_name>
    <role>Study Chair</role>
    <affiliation>US Military HIV Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya Med. Research Inst./Walter Reed Project, Clinical Research Centre, Off Hospital Road. Kericho</name>
      <address>
        <city>Kericho</city>
        <zip>20200</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) CRS</name>
      <address>
        <city>Mbeya</city>
        <zip>025</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University Walter Reed Project (MUWRP)</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information about HIV preventive vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/LaVacunaPreventivaContraElSVIH_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca de las vacunas preventivas</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1562</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med. 2003 May;3(3):183-93. Review.</citation>
    <PMID>12699356</PMID>
  </reference>
  <reference>
    <citation>Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 2002 Jun 28;296(5577):2354-60. Review.</citation>
    <PMID>12089434</PMID>
  </reference>
  <reference>
    <citation>Stratov I, DeRose R, Purcell DF, Kent SJ. Vaccines and vaccine strategies against HIV. Curr Drug Targets. 2004 Jan;5(1):71-88. Review.</citation>
    <PMID>14738219</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 22, 2005</study_first_submitted>
  <study_first_submitted_qc>July 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2005</study_first_posted>
  <disposition_first_submitted>July 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 18, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2013</disposition_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

